Naslov
Invasive aspergillosis in patients with hematological malignancies in Czech and Slovak Republics: fungal infection database (FIND) analysis (2001–2011) – an update

Autori
Weinbergerova, Barbora ; Racil, Zdenek ; Kocmanova, Iva ; Mužik, J ; Kouba, M ; Vydra, J ; Drgona, L ; Masarova, L ; Gabzdilova, J ; Guman, T ; Ziakova, B ; Bojtarova, E ; Forsterova, K ; Haber, J ; Chrenkova, V ; Sedlacek, P ; Novak, J ; Heklova, R ; Mudry, P ; Sejnova, D ; Vokurka, S ; Karas, M ; Mallatova, N ; Chocholova, A ; Horakova, J ; Ligova, A ; Ostojić, Alen ; Vrhovac, Radovan ; Timr, P ; Gredelj Šimec, Njetočka ; Rolencova, M ; Kandrnal, V ; Cetkovsky, P ; Mayer, J ;

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Mycoses - Special Issue: Abstracts of the 6th Trends in Medical Mycology, 11–14 October 2013, Copenhagen, Denmark, Volume 56, Issue Supplement s3, pages 55–167, October 2013 / Cornely, O. A. ; Meis, J. F. G. M. ; Schaller, M. - : Blackwell Publishing, 2013, 121-122

Skup
6th Trends in Medical Mycology

Mjesto i datum
Kopenhagen, Danska, 11.10.2013. - 14.10.2013

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Invasive aspergillosis; Hematologic malignancies

Sažetak
Objectives: “Fungal InfectioN Database” (FIND) represents international database of invasive fungal infections in Czech and Slovak hematooncological departments. FIND - aspergillus covers all case of invasive aspergillosis (IA) in participating centers since 2001. Methods: The goal of our retrospective analysis was to evaluate incidence, early diagnostic procedures and effect of antifungal therapy in proven and probable IA that occurred in 16 institutions participating in FIND database between 2001–2011. Till 2009 we followed EORTC/MSG 2002 and from 2010 EORTC/MSG 2008 criteria in evaluation of IA diagnosis and therapy response. Results: 256 probable and 58 proven IA (91% isolated pulmonary IA, IPA) have been documented. Prolonged and profound neutropenia (61%) and long-term use of corticosteroids (28%) were identified as the major risk factors of IA. 68% pts. had consecutive positivity of serum-galactomannan (S-GM) (OD index >0.5). 83% pts. with IPA and bronchoalveolar lavage (BAL) had positive GM in BAL fluid (OD index >0.5). In pts. with IPA only 7.6% BAL fluids and 8.4% sputum samples had positive microscopic result for filamentous fungi and 2.2% BAL fluids and 1.8% sputum samples had positive culture for Aspergillus spp. The primary antifungal therapy of IA was used in 89% pts. - 41% voriconazole (VORI), 7% echinocandins (ECHINO), 23% VORI+ECHINO, 7% amphotericine B deoxycholate (C-AMB) and 9% lipid- based AMB (LBA). Overall RR to primary therapy of IA was 46% - VORI 55%, VORI+ECHINO 54%, C-AMB 35%, LBA 39%, ECHINO 25%. There was a statistically significant difference in overall RR to targeted therapy in pts. with neutrophil count <0.1 and >1.0x10e9/L at the end of therapy (21% vs. 71%). The overall mortality rate was 61%, with 39% attributable to IA. Conclusion: On the basis of our analysis we confirm typical risk factors for IA and critical role of S-GM and CT for early diagnosis and prompt start of antifungal therapy of IA. A reasonable treatment response was achieved using VORI, VORI+ECHINO or LBA in primary therapy of IA. We have confirmed neutropenia at the end of antifungal therapy as the major predictive factor for therapeutic response. On behalf of CELL - The Czech leukemia study group for life.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA